REFERENCES
1. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008;31:247-69.
2. Tur C, Goodkin O, Altmann DR, et al. Longitudinal evidence for anterograde trans-synaptic degeneration after optic neuritis. Brain 2016;139:816-28.
4. Gabilondo I, Martínez-Lapiscina EH, Martínez-Heras E, et al. Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. Ann Neurol 2014;75:98-107.
5. Schmidt D, Meyer JH, Brandi-Dohrn J. Wide-spread myelinated nerve fibers of the optic disc: do they influence the development of myopia? Int Ophthalmol 1996;20:263-8.
6. Green AJ, McQuaid S, Hauser SL, Allen IV, Lyness R. Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration. Brain 2010;133:1591-601.
7. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-85.
8. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997;120:393-9.
9. Kornek B, Storch M K, Weissert R, Schmidbauer i M, Lassmann H, et al. (2000). “[J]. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions.”. Am J Pathol 2000;157:267-76.
10. Quigley HA, Davis EB, Anderson DR. Descending optic nerve degeneration in primates. Invest Ophthalmol Vis Sci 1977;16:841-9.
12. Keltner JL, Johnson CA, Spurr JO, Beck RW. Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Arch Ophthalmol 1993;111:231-4.
13. Tintoré M, Montalban X. The optic nerve should be included as one of the typical CNS regions for establishing dissemination in space when diagnosing MS - No. Mult Scler 2018;24:123-5.
14. Galetta SL, Balcer LJ. The optic nerve should be included as one of the typical CNS regions for establishing dissemination in space when diagnosing MS - Yes. Mult Scler 2018;24:121-2.
15. Toussaint D, Périer O, Verstappen A, Bervoets S. Clinicopathological study of the visual pathways, eyes, and cerebral hemispheres in 32 cases of disseminated sclerosis. J Clin Neuroophthalmol 1983;3:211-20.
16. Bischof A, Caverzasi E, Cordano C, Hauser SL, Henry RG. Advances in imaging multiple sclerosis. Semin Neurol 2017;37:538-45.
17. Parisi V. Correlation between morphological and functional retinal impairment in patients affected by ocular hypertension, glaucoma, demyelinating optic neuritis and Alzheimer’s disease. Semin Ophthalmol 2003;18:50-7.
18. Trip SA, Schlottmann PG, Jones SJ, et al. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol 2005;58:383-91.
19. Henderson AP, Altmann DR, Trip AS, et al. A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain 2010;133:2592-602.
20. Klistorner A, Arvind H, Garrick R, Graham SL, Paine M, Yiannikas C. Interrelationship of optical coherence tomography and multifocal visual-evoked potentials after optic neuritis. Invest Ophthalmol Vis Sci 2010;51:2770-7.
21. Gelfand JM, Goodin DS, Boscardin WJ, Nolan R, Cuneo A, Green AJ. Retinal axonal loss begins early in the course of multiple sclerosis and is similar between progressive phenotypes. PLoS One 2012;7:e36847.
22. Costello F, Coupland S, Hodge W, et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 2006;59:963-9.
23. Costello F, Hodge W, Pan YI, Eggenberger E, Coupland S, Kardon RH. Tracking retinal nerve fiber layer loss after optic neuritis: a prospective study using optical coherence tomography. Mult Scler 2008;14:893-905.
24. Kupersmith MJ, Mandel G, Anderson S, Meltzer DE, Kardon R. Baseline, one and three month changes in the peripapillary retinal nerve fiber layer in acute optic neuritis: relation to baseline vision and MRI. J Neurol Sci 2011;308:117-23.
25. Petzold A, Balcer LJ, Calabresi PA, et al. Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 2017;16:797-812.
26. Gabilondo I, Martínez-Lapiscina EH, Fraga-Pumar E, et al. Dynamics of retinal injury after acute optic neuritis. Ann Neurol 2015;77:517-28.
27. Rucker CW. Sheathing of the retinal veins in multiple sclerosis. Review of pertinent literature. Mayo Clin Proc 1972;47:335-40.
28. Frisén L, Hoyt WF. Insidious atrophy of retinal nerve fibers in multiple sclerosis. Funduscopic identification in patients with and without visual complaints. Arch Ophthalmol 1974;92:91-7.
29. Kerrison JB, Flynn T, Green WR. Retinal pathologic changes in multiple sclerosis. Retina 1994;14:445-51.
30. Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM. Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. Brain 2001;124:1813-20.
31. Blumenthal EZ, Parikh RS, Pe’er J, et al. Retinal nerve fibre layer imaging compared with histological measurements in a human eye. Eye (Lond) 2009;23:171-5.
32. Audoin B, Fernando KT, Swanton JK, Thompson AJ, Plant GT, Miller DH. Selective magnetization transfer ratio decrease in the visual cortex following optic neuritis. Brain 2006;129:1031-9.
33. Reich DS, Smith SA, Gordon-Lipkin EM, et al. Damage to the optic radiation in multiple sclerosis is associated with retinal injury and visual disability. Arch Neurol 2009;66:998-1006.
34. Brück W, Porada P, Poser S, et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995;38:788-96.
35. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-17.
36. Popescu BF, Lucchinetti CF. Pathology of demyelinating diseases. Annu Rev Pathol 2012;7:185-217.
37. Calabresi PA, Balcer LJ, Frohman EM. Retinal pathology in multiple sclerosis: insight into the mechanisms of neuronal pathology. Brain 2010;133:1575-7.
38. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009;132:1175-89.
39. Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Brück W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002;125:2202-12.
41. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005;128:2705-12.
42. Parisi V, Manni G, Centofanti M, et al. Correlation between optical coherence tomography, pattern electroretinogram, and visual evoked potentials in open-angle glaucoma patients. Ophthalmology 2001;108:905-12.
43. Fisher JB, Jacobs DA, Markowitz CE, et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 2006;113:324-32.
44. van Dijkman SC, de Jager NCB, Rauwé WM, Danhof M, Della Pasqua O. Effect of age-related factors on the pharmacokinetics of lamotrigine and potential implications for maintenance dose optimisation in future clinical trials. Clin Pharmacokinet 2018;57:1039-53.
45. Costello F, Hodge W, Pan YI, Freedman M, DeMeulemeester C. Differences in retinal nerve fiber layer atrophy between multiple sclerosis subtypes. J Neurol Sci 2009;281:74-9.
46. Petzold A, de Boer JF, Schippling S, et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 2010;9:921-32.
47. Martinez-Lapiscina EH, Arnow S, Wilson JA, et al. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurol 2016;15:574-84.
48. Cordano C, Nourbakhsh B, Devereux M, et al. pRNFL as a marker of disability worsening in the medium/long term in patients with MS. Neurol Neuroimmunol Neuroinflamm 2018;6:e533.
49. DeLuca GC, Ebers GC, Esiri MM. Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. Brain 2004;127:1009-18.
50. Petracca M, Cordano C, Cellerino M, et al. Retinal degeneration in primary-progressive multiple sclerosis: A role for cortical lesions? Mult Scler 2017;23:43-50.
51. Caverzasi E, Cordano C, Zhu AH, et al. Imaging correlates of visual function in multiple sclerosis. PLoS One 2020;15:e0235615.
52. Saidha S, Sotirchos ES, Ibrahim MA, et al. Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol 2012;11:963-72.
53. Gelfand JM, Nolan R, Schwartz DM, Graves J, Green AJ. Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain 2012;135:1786-93.
54. Balk LJ, Killestein J, Polman CH, Uitdehaag BM, Petzold A. Microcystic macular oedema confirmed, but not specific for multiple sclerosis. Brain 2012;135:e226-7.
55. Green AJ, Schwartz D, Gelfand J. Reply: microcysts in the inner nuclear layer from optic atrophy are caused by retrograde trans-synaptic degeneration combined with vitreous traction on the retinal surface. Brain 2013;136:e261.
56. Gaudric A, Ducos de Lahitte G, Cohen SY, Massin P, Haouchine B. Optical coherence tomography in group 2A idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol 2006;124:1410-9.
57. Abegg M, Dysli M, Wolf S, Kowal J, Dufour P, Zinkernagel M. Microcystic macular edema: retrograde maculopathy caused by optic neuropathy. Ophthalmology 2014;121:142-9.
58. Wolff B, Basdekidou C, Vasseur V, Mauget-Faÿsse M, Sahel JA, Vignal C. Retinal inner nuclear layer microcystic changes in optic nerve atrophy: a novel spectral-domain OCT finding. Retina 2013;33:2133-8.
59. Barboni P, Carelli V, Savini G, Carbonelli M, La Morgia C, Sadun AA. Microcystic macular degeneration from optic neuropathy: not inflammatory, not trans-synaptic degeneration. Brain 2013;136:e239.
60. vanBuren JM. Trans-synaptic retrograde degeneration in the visual system of primates. J Neurol Neurosurg Psychiatry 1963;26:402-9.
61. Knier B, Schmidt P, Aly L, et al. Retinal inner nuclear layer volume reflects response to immunotherapy in multiple sclerosis. Brain 2016;139:2855-63.
62. Cellerino M, Cordano C, Boffa G, et al. Relationship between retinal inner nuclear layer, age, and disease activity in progressive MS. Neurol Neuroimmunol Neuroinflamm 2019;6:e596.
63. Cordano C, Yiu HH, Oertel FC, et al. Retinal INL thickness in multiple sclerosis: a mere marker of neurodegeneration? Ann Neurol 2020; doi: 10.1002/ana.25933.
64. Le Scanff J, Sève P, Renoux C, Broussolle C, Confavreux C, Vukusic S. Uveitis associated with multiple sclerosis. Mult Scler 2008;14:415-7.
65. Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology 2012;78:672-80.
66. Dudek SM, Jacobson JR, Chiang ET, et al. Pulmonary endothelial cell barrier enhancement by sphingosine 1-phosphate: roles for cortactin and myosin light chain kinase. J Biol Chem 2004;279:24692-700.
67. Sanna MG, Wang SK, Gonzalez-Cabrera PJ, et al. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol 2006;2:434-41.
68. Sheehy CK, Bensinger ES, Romeo A, et al. Fixational microsaccades: a quantitative and objective measure of disability in multiple sclerosis. Mult Scler 2020;26:343-53.
69. Serra A, Petzold A. Can stability of visual fixation be a measure for disability in multiple sclerosis? Mult Scler 2020;26:264-5.
70. Bennett JL, de Seze J, Lana-Peixoto M, et al. Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. Mult Scler 2015;21:678-88.
71. Green AJ, Cree BA. Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis. J Neurol Neurosurg Psychiatry 2009;80:1002-5.
72. Schneider E, Zimmermann H, Oberwahrenbrock T, et al. Optical coherence tomography reveals distinct patterns of retinal damage in neuromyelitis optica and multiple sclerosis. PLoS One 2013;8:e66151.
73. Ratchford JN, Quigg ME, Conger A, et al. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology 2009;73:302-8.
74. Shen T, You Y, Arunachalam S, et al. Differing structural and functional patterns of optic nerve damage in multiple sclerosis and neuromyelitis optica spectrum disorder. Ophthalmology 2019;126:445-53.
75. Oertel FC, Kuchling J, Zimmermann H, et al. Microstructural visual system changes in AQP4-antibody-seropositive NMOSD. Neurol Neuroimmunol Neuroinflamm 2017;4:e334.
76. Shindler KS, Guan Y, Ventura E, Bennett J, Rostami A. Retinal ganglion cell loss induced by acute optic neuritis in a relapsing model of multiple sclerosis. Mult Scler 2006;12:526-32.
77. Shindler KS, Ventura E, Dutt M, Rostami A. Inflammatory demyelination induces axonal injury and retinal ganglion cell apoptosis in experimental optic neuritis. Exp Eye Res 2008;87:208-13.
78. Quinn TA, Dutt M, Shindler KS. Optic neuritis and retinal ganglion cell loss in a chronic murine model of multiple sclerosis. Front Neurol 2011;2:50.
79. Smith AW, Rohrer B, Wheless L, et al. Calpain inhibition reduces structural and functional impairment of retinal ganglion cells in experimental optic neuritis. J Neurochem 2016;139:270-84.
80. Kaushansky N, Zilkha-Falb R, Hemo R, et al. Pathogenic T cells in MOBP-induced murine EAE are predominantly focused to recognition of MOBP21F and MOBP27P epitopic residues. Eur J Immunol 2007;37:3281-92.
81. Soares RM, Dias AT, De Castro SB, et al. Optical neuritis induced by different concentrations of myelin oligodendrocyte glycoprotein presents different profiles of the inflammatory process. Autoimmunity 2013;46:480-5.
82. Cruz-Herranz A, Dietrich M, Hilla AM, et al. Monitoring retinal changes with optical coherence tomography predicts neuronal loss in experimental autoimmune encephalomyelitis. J Neuroinflammation 2019;16:203.
83. Guo X, Harada C, Namekata K, et al. Delayed onset of experimental autoimmune encephalomyelitis in Olig1 deficient mice. PLoS One 2010;5:e13083.
84. Guan Y, Shindler KS, Tabuena P, Rostami AM. Retinal ganglion cell damage induced by spontaneous autoimmune optic neuritis in MOG-specific TCR transgenic mice. J Neuroimmunol 2006;178:40-8.
85. Pöllinger B, Krishnamoorthy G, Berer K, et al. Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J Exp Med 2009;206:1303-16.
86. Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med 2003;197:1073-81.
87. Shao H, Huang Z, Sun SL, Kaplan HJ, Sun D. Myelin/oligodendrocyte glycoprotein-specific T-cells induce severe optic neuritis in the C57BL/6 mouse. Invest Ophthalmol Vis Sci 2004;45:4060-5.
88. de Rosbo NK, Kaye JF, Eisenstein M, et al. The myelin-associated oligodendrocytic basic protein region MOBP15-36 encompasses the immunodominant major encephalitogenic epitope(s) for SJL/J mice and predicted epitope(s) for multiple sclerosis-associated HLA-DRB1*1501. J Immunol 2004;173:1426-35.
89. Horstmann L, Kuehn S, Pedreiturria X, et al. Microglia response in retina and optic nerve in chronic experimental autoimmune encephalomyelitis. J Neuroimmunol 2016;298:32-41.
90. Jin J, Smith MD, Kersbergen CJ, et al. Glial pathology and retinal neurotoxicity in the anterior visual pathway in experimental autoimmune encephalomyelitis. Acta Neuropathol Commun 2019;7:125.
91. Manogaran P, Samardzija M, Schad AN, et al. Retinal pathology in experimental optic neuritis is characterized by retrograde degeneration and gliosis. Acta Neuropathol Commun 2019;7:116.
92. Manogaran P, Walker-Egger C, Samardzija M, et al. Exploring experimental autoimmune optic neuritis using multimodal imaging. Neuroimage 2018;175:327-39.
93. Horstmann L, Schmid H, Heinen AP, Kurschus FC, Dick HB, Joachim SC. Inflammatory demyelination induces glia alterations and ganglion cell loss in the retina of an experimental autoimmune encephalomyelitis model. J Neuroinflammation 2013;10:120.
94. Knier B, Rothhammer V, Heink S, et al. Neutralizing IL-17 protects the optic nerve from autoimmune pathology and prevents retinal nerve fiber layer atrophy during experimental autoimmune encephalomyelitis. J Autoimmun 2015;56:34-44.
95. Malik S, Want MY, Awasthi A. The emerging roles of gamma-delta T cells in tissue inflammation in experimental autoimmune encephalomyelitis. Front Immunol 2016;7:14.
96. Larabee CM, Hu Y, Desai S, et al. Myelin-specific Th17 cells induce severe relapsing optic neuritis with irreversible loss of retinal ganglion cells in C57BL/6 mice. Mol Vis 2016;22:332-41.
97. Locri F, Cammalleri M, Pini A, Dal Monte M, Rusciano D, Bagnoli P. Further evidence on efficacy of diet supplementation with fatty acids in ocular pathologies: insights from the EAE model of optic neuritis. Nutrients 2018;10:1447.
98. Matsuda R, Kezuka T, Nishiyama C, et al. Interleukin-10 gene-transfected mature dendritic cells suppress murine experimental autoimmune optic neuritis. Invest Ophthalmol Vis Sci 2012;53:7235-45.
99. Bullard DC, Hu X, Adams JE, Schoeb TR, Barnum SR. p150/95 (CD11c/CD18) expression is required for the development of experimental autoimmune encephalomyelitis. Am J Pathol 2007;170:2001-8.
100. Koh DR, Fung-Leung WP, Ho A, Gray D, Acha-Orbea H, Mak TW. Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-/- mice. Science 1992;256:1210-3.
101. Hjelmström P, Juedes AE, Fjell J, Ruddle NH. B-cell-deficient mice develop experimental allergic encephalomyelitis with demyelination after myelin oligodendrocyte glycoprotein sensitization. J Immunol 1998;161:4480-3.
102. Brambilla R, Dvoriantchikova G, Barakat D, Ivanov D, Bethea JR, Shestopalov VI. Transgenic inhibition of astroglial NF-κB protects from optic nerve damage and retinal ganglion cell loss in experimental optic neuritis. J Neuroinflammation 2012;9:213.
103. Guo X, Namekata K, Kimura A, Harada C, Harada T. The renin-angiotensin system regulates neurodegeneration in a mouse model of optic neuritis. Am J Pathol 2017;187:2876-85.
104. Itoh N, Itoh Y, Tassoni A, et al. Cell-specific and region-specific transcriptomics in the multiple sclerosis model: focus on astrocytes. Proc Natl Acad Sci U S A 2018;115:E302-9.
105. Tassoni A, Farkhondeh V, Itoh Y, Itoh N, Sofroniew MV, Voskuhl RR. The astrocyte transcriptome in EAE optic neuritis shows complement activation and reveals a sex difference in astrocytic C3 expression. Sci Rep 2019;9:10010.
106. Khan RS, Baumann B, Dine K, et al. Dexras1 deletion and iron chelation promote neuroprotection in experimental optic neuritis. Sci Rep 2019;9:11664.
107. Larabee CM, Desai S, Agasing A, et al. Loss of Nrf2 exacerbates the visual deficits and optic neuritis elicited by experimental autoimmune encephalomyelitis. Mol Vis 2016;22:1503-13.
108. Palani CD, Fouda AY, Liu F, et al. Deletion of arginase 2 ameliorates retinal neurodegeneration in a mouse model of multiple sclerosis. Mol Neurobiol 2019;56:8589-602.
109. Guo X, Harada C, Namekata K, et al. Spermidine alleviates severity of murine experimental autoimmune encephalomyelitis. Invest Ophthalmol Vis Sci 2011;52:2696-703.
110. Guo X, Namekata K, Kimura A, et al. Brimonidine suppresses loss of retinal neurons and visual function in a murine model of optic neuritis. Neurosci Lett 2015;592:27-31.
111. Guy J, Qi X, Hauswirth WW. Adeno-associated viral-mediated catalase expression suppresses optic neuritis in experimental allergic encephalomyelitis. Proc Natl Acad Sci U S A 1998;95:13847-52.
112. Khan RS, Dine K, Das Sarma J, Shindler KS. SIRT1 activating compounds reduce oxidative stress mediated neuronal loss in viral induced CNS demyelinating disease. Acta Neuropathol Commun 2014;2:3.
113. Khan RS, Dine K, Geisler JG, Shindler KS. Mitochondrial uncoupler prodrug of 2,4-dinitrophenol, MP201, prevents neuronal damage and preserves vision in experimental optic neuritis. Oxid Med Cell Longev 2017;2017:7180632.
114. McDougald DS, Dine KE, Zezulin AU, Bennett J, Shindler KS. SIRT1 and NRF2 gene transfer mediate distinct neuroprotective effects upon retinal ganglion cell survival and function in experimental optic neuritis. Invest Ophthalmol Vis Sci 2018;59:1212-20.
115. Qi X, Sun L, Lewin AS, Hauswirth WW, Guy J. Long-term suppression of neurodegeneration in chronic experimental optic neuritis: antioxidant gene therapy. Invest Ophthalmol Vis Sci 2007;48:5360-70.
116. Talla V, Yu H, Chou TH, et al. NADH-dehydrogenase type-2 suppresses irreversible visual loss and neurodegeneration in the EAE animal model of MS. Mol Ther 2013;21:1876-88.
117. Talla V, Porciatti V, Chiodo V, Boye SL, Hauswirth WW, Guy J. Gene therapy with mitochondrial heat shock protein 70 suppresses visual loss and optic atrophy in experimental autoimmune encephalomyelitis. Invest Ophthalmol Vis Sci 2014;55:5214-26.
118. Talla V, Koilkonda R, Porciatti V, et al. Complex I subunit gene therapy with NDUFA6 ameliorates neurodegeneration in EAE. Invest Ophthalmol Vis Sci 2015;56:1129-40.
119. Talla V, Koilkonda R, Guy J. Gene therapy with single-subunit yeast NADH-ubiquinone oxidoreductase (NDI1) improves the visual function in experimental autoimmune encephalomyelitis (EAE) mice model of multiple sclerosis (MS). Mol Neurobiol 2020;57:1952-65.
120. Shindler KS, Ventura E, Rex TS, Elliott P, Rostami A. SIRT1 activation confers neuroprotection in experimental optic neuritis. Invest Ophthalmol Vis Sci 2007;48:3602-9.
121. Shindler KS, Ventura E, Dutt M, Elliott P, Fitzgerald DC, Rostami A. Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J Neuroophthalmol 2010;30:328-39.
122. Dietrich M, Helling N, Hilla A, et al. Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model. J Neuroinflammation 2018;15:71.
123. Fonseca-Kelly Z, Nassrallah M, Uribe J, et al. Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis. Front Neurol 2012;3:84.
124. Khan RS, Dine K, Wessel H, Brown L, Shindler KS. Effects of varying intranasal treatment regimens in ST266-mediated retinal ganglion cell neuroprotection. J Neuroophthalmol 2019;39:191-9.
125. Dietrich M, Koska V, Hecker C, et al. Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis. Brain 2020;143:1127-42.
126. Schirmer L, Möbius W, Zhao C, et al. Oligodendrocyte-encoded Kir4.1 function is required for axonal integrity. Elife 2018;7:e36428.
127. Takahashi H, Okuda S, Tamura M, Kamei S, Aizawa R, Kobayashi T. Prophylactic treatment with intravenous immunoglobulin attenuates experimental optic neuritis in mice. Biol Pharm Bull 2019;42:173-8.
128. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012;366:1000-9.
129. Vollmer TL, Sorensen PS, Selmaj K, et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol 2014;261:773-83.
130. Wilmes AT, Reinehr S, Kühn S, et al. Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model. J Neuroinflammation 2018;15:183.
131. Lo AC, Black JA, Waxman SG. Neuroprotection of axons with phenytoin in experimental allergic encephalomyelitis. Neuroreport 2002;13:1909-12.
132. Raftopoulos R, Hickman S J, Toosy A, et al. Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2016;15:259-69.
133. Gresle MM, Liu Y, Kilpatrick TJ, et al. Blocking LINGO-1 in vivo reduces degeneration and enhances regeneration of the optic nerve. Mult Scler J Exp Transl Clin 2016;2:2055217316641704.
134. Cadavid D, Balcer L, Galetta S, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2017;16:189-99.
135. Green AJ, Gelfand JM, Cree BA, et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet 2017;390:2481-9.
136. Diem R, Demmer I, Boretius S, et al. Autoimmune optic neuritis in the common marmoset monkey: comparison of visual evoked potentials with MRI and histopathology. Invest Ophthalmol Vis Sci 2008;49:3707-14.
137. Boretius S, Schmelting B, Watanabe T, et al. Monitoring of EAE onset and progression in the common marmoset monkey by sequential high-resolution 3D MRI. NMR Biomed 2006;19:41-9.
138. Boretius S, Gadjanski I, Demmer I, et al. MRI of optic neuritis in a rat model. Neuroimage 2008;41:323-34.
139. Wu Q, Butzkueven H, Gresle M, et al. MR diffusion changes correlate with ultra-structurally defined axonal degeneration in murine optic nerve. Neuroimage 2007;37:1138-47.
140. Nishioka C, Liang HF, Chung CF, Sun SW. Disease stage-dependent relationship between diffusion tensor imaging and electrophysiology of the visual system in a murine model of multiple sclerosis. Neuroradiology 2017;59:1241-50.
141. Wuerfel E, Infante-Duarte C, Glumm R, Wuerfel JT. Gadofluorine M-enhanced MRI shows involvement of circumventricular organs in neuroinflammation. J Neuroinflammation 2010;7:70.
142. Beaulieu C. The basis of anisotropic water diffusion in the nervous system - a technical review. NMR Biomed 2002;15:435-55.
143. Sun SW, Liang HF, Schmidt RE, Cross AH, Song SK. Selective vulnerability of cerebral white matter in a murine model of multiple sclerosis detected using diffusion tensor imaging. Neurobiol Dis 2007;28:30-8.
144. Chiang CW, Wang Y, Sun P, et al. Quantifying white matter tract diffusion parameters in the presence of increased extra-fiber cellularity and vasogenic edema. Neuroimage 2014;101:310-9.
145. Nishioka C, Liang HF, Barsamian B, Sun SW. Sequential phases of RGC axonal and somatic injury in EAE mice examined using DTI and OCT. Mult Scler Relat Disord 2019;27:315-23.
146. Lin TH, Chiang CW, Perez-Torres CJ, et al. Diffusion MRI quantifies early axonal loss in the presence of nerve swelling. J Neuroinflammation 2017;14:78.
147. Lin TH, Kim JH, Perez-Torres C, et al. Axonal transport rate decreased at the onset of optic neuritis in EAE mice. Neuroimage 2014;100:244-53.
148. Gadjanski I, Boretius S, Williams SK, et al. Role of n-type voltage-dependent calcium channels in autoimmune optic neuritis. Ann Neurol 2009;66:81-93.
149. Darquié A, Poline JB, Poupon C, Saint-Jalmes H, Le Bihan D. Transient decrease in water diffusion observed in human occipital cortex during visual stimulation. Proc Natl Acad Sci U S A 2001;98:9391-5.
150. Tsurugizawa T, Ciobanu L, Le Bihan D. Water diffusion in brain cortex closely tracks underlying neuronal activity. Proc Natl Acad Sci U S A 2013;110:11636-41.
151. Spees WM, Lin TH, Song SK. White-matter diffusion fMRI of mouse optic nerve. Neuroimage 2013;65:209-15.
152. Lin T H, Spees W M, Chiang C W, et al. Diffusion fMRI detects white-matter dysfunction in mice with acute optic neuritis. Neurobiol Dis 2014;67:1-8.
153. Duong TQ. Magnetic resonance imaging of the retina: from mice to men. Magn Reson Med 2014;71:1526-30.
154. Matsushima GK, Morell P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 2001;11:107-16.
155. Praet J, Guglielmetti C, Berneman Z, Van der Linden A, Ponsaerts P. Cellular and molecular neuropathology of the cuprizone mouse model: clinical relevance for multiple sclerosis. Neurosci Biobehav Rev 2014;47:485-505.
156. Namekata K, Kimura A, Harada C, Yoshida H, Matsumoto Y, Harada T. Dock3 protects myelin in the cuprizone model for demyelination. Cell Death Dis 2014;5:e1395.
157. Hainz N, Becker P, Rapp D, et al. Probenecid-treatment reduces demyelination induced by cuprizone feeding. J Chem Neuroanat 2017;85:21-6.
158. Bagchi B, Al-Sabi A, Kaza S, et al. Disruption of myelin leads to ectopic expression of K(V)1.1 channels with abnormal conductivity of optic nerve axons in a cuprizone-induced model of demyelination. PLoS One 2014;9:e87736.
159. Kojima W, Hayashi K. Changes in the axo-glial junctions of the optic nerves of cuprizone-treated mice. Histochem Cell Biol 2018;149:529-36.
